Study of a Latanoprost Ocular Implant for Treatment of Open Angle Glaucoma or Ocular Hypertension.
Status:
Recruiting
Trial end date:
2023-08-04
Target enrollment:
Participant gender:
Summary
This is an open label, single dose (100 ng/day) study to assess the safety, tolerability and
biodegradation of the PA5436 Latanoprost FA SR Ocular Implant in adults who have OAG or OHT.